Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 41.8
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It is developing L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Limited and...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is overpriced on P/FCF.
Data is available to registered users only
Buy
Sell